Clinical Topics   /   Research

VA Patients Lack Testing to Optimize CLL Treatment

By U.S. Medicine

SALT LAKE CITY — The presence of deletion 17p (del17), determined by chromosome analysis and/or fluorescence in situ hybridization (FISH), is a strong negative prognostic marker in chronic lymphocytic leukemia (CLL), according to a report in the Journal of Clinical Oncology.1

Prior to the introduction of novel agents such as ibrutinib and venetoclax, the clinical utility of cytogenetics/FISH was limited by the absence of chemoimmunotherapy regimens that were proven effective in patients with del17.

A study team led by Salt Lake City VAMC researchers noted that testing practices for chromosomal aberrations since the introduction of novel agents have not been reported and focused on cytogenetic/FISH trends in a nationwide cohort of veterans diagnosed with CLL.

The VA Clinical Cancer Registry was used to identify CLL patients diagnosed 2008-2015 and receiving care at VA. At the same time, electronic medical records were used to determine cytogenetic/FISH testing (lab records), treatment histories (pharmacy dispensation records), and evidence of system use (heme-onc notes).

Cytogenetic/FISH testing was identified by presence of specific keywords in the test name or Logical Observation Identifiers Names and Codes (LOINC) descriptions, then validated by human annotation. The testing rates were reported for the entire cohort, at time of diagnosis, time of regimen initiation (including the 12 months preceding initiation), during the novel era (2014-2015) and prior (2008-2013), the authors noted.

Results indicated that, from 2008 to 2015, 3,638 CLL patients were diagnosed and received care at VA. Documented records of treatment regimens were available for 1,562 patients who received a total of 2,929 treatment regimens. Yet, only 24% (998) of patients were tested at any point in time during their care at the VA, 17% (622) were tested at time of diagnosis, and 19% (542) of treatment courses were preceded by cytogenetic/FISH testing.

The study group found No testing differences existed following the introduction of the novel agents at diagnosis (both ˜ 17%) or prior to regimen initiation (20% vs. 16%).

“Our study suggests CLL patients diagnosed and receiving care at the VA are not routinely undergoing cytogenetics/FISH testing at diagnosis or prior to treatment,” researchers explained. “Changing this practice pattern will personalize treatments so that del17 CLL patients receive less toxic and more effective therapies.”

1Halwani AS, Burningham Z, Rasmussen KM, Patil V, et. Al. Cytogenetic and fluorescence in situ hybridization testing in veterans with chronic lymphocytic leukemia. Journal of Clinical Oncology 35, No. 15_suppl (May 2017) 7526-7526. DOI: 10.1200/JCO.2017.35.15_suppl.7526.

Related Articles

VHA’s Type 1 Diabetes Telehealth Care Saves Time, Money

ATLANTA — About 5% of the United States population has been diagnosed with type 1 diabetes, and the great majority are diagnosed before age 25. Since a diabetes diagnosis prevents enlistment in the military, relatively few veterans have the condition compared to type 2 diabetes, which affects about a fourth of VHA patients.

Tele-Critical Care Helps MTF Expand to More Complex Surgeries

SAN DIEGO — Most research suggests that hospitals with intensivists, board-certified physician who provides specialized care for critically ill patients save more lives.

U.S. Medicine Recommends

More From research


First-Ever Study Focuses on How Well VHA Cares for TIA Patients

INDIANAPOLIS — While many healthcare systems measure the quality of their stroke care, looking at performance early in the vascular disease process can help avoid acute events altogether.


Link Between Pain, Brain Disruption in Gulf War Veterans

BRONX, NY — For patients with chronic kidney disease (CKD), living more than 30 miles from their nephrologist is associated with many unfavorable outcomes. They have lower rates of clinic visit adherence, more limited access... View Article


Early Relapse After AHCT Bad Sign in Multiple Myeloma

BRONX, NY — For patients with chronic kidney disease (CKD), living more than 30 miles from their nephrologist is associated with many unfavorable outcomes. They have lower rates of clinic visit adherence, more limited access... View Article


Laparoscopic, Robotic Surgeries Equivalent for Pancreatic Cancer

Pancreatic cancer patients increasingly are receiving minimally invasive pancreaticoduodenectomy (MIPD).


Living With a Mystery Disease: One Woman’s Story

At 31, Susan Thornton developed an itchy rash around her waist.

Facebook Comment

Subscribe to U.S. Medicine Print Magazine

U.S. Medicine is mailed free each month to physicians, pharmacists, nurse practitioners, physician assistants and administrators working for Veterans Affairs, Department of Defense and U.S. Public Health Service.

Subscribe Now

Receive Our Email Newsletter

Stay informed about federal medical news, clinical updates and reports on government topics for the federal healthcare professional.

Sign Up